Loading...
Please wait, while we are loading the content...
Similar Documents
The changing landscape in the treatment of metastatic castration-resistant prostate cancer
| Content Provider | SAGE Publishing |
|---|---|
| Author | El-Amm, Joelle Aragon-Ching, Jeanny B. |
| Copyright Year | 2012 |
| Abstract | The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/1758834012458137?download=true |
| Starting Page | 25 |
| Ending Page | 40 |
| Page Count | 16 |
| ISSN | 17588359 |
| Issue Number | 1 |
| Volume Number | 5 |
| Journal | Therapeutic Advances in Medical Oncology (TAM) |
| e-ISSN | 17588359 |
| DOI | 10.1177/1758834012458137 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2012-09-03 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © The Author(s), 2012 |
| Subject Keyword | vaccine therapy Androgen deprivation therapy chemotherapy metastatic castration-resistant prostate cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
